Harrison, S. A., Neff, G., Guy, C., Bashir, M., Paredes, A., Frias, J., … Lieu, H. (2020). Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis. In JOURNAL OF HEPATOLOGY (Vol. 73, pp. S114–S115).

Harrison, Stephen A., Guy Neff, Cynthia Guy, Mustafa Bashir, Angelo Paredes, Juan Frias, Ziad H. Younes, et al. “Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis.” In JOURNAL OF HEPATOLOGY, 73:S114–15, 2020.

Harrison SA, Neff G, Guy C, Bashir M, Paredes A, Frias J, et al. Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis. In: JOURNAL OF HEPATOLOGY. 2020. p. S114–5.

Harrison, Stephen A., et al. “Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis.” JOURNAL OF HEPATOLOGY, vol. 73, 2020, pp. S114–15.

Harrison SA, Neff G, Guy C, Bashir M, Paredes A, Frias J, Younes ZH, Trotter JF, Gunn NT, Moussa S, Kohli A, Nelson K, Gottwald M, Chang W, Yan A, Depaoli A, Ling L, Lieu H. Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis. JOURNAL OF HEPATOLOGY. 2020. p. S114–S115.